Patient characteristics
Characteristics . | No. . |
|---|---|
| Total enrolled | 20 |
| Women/men | 11/9 |
| Mean age, y (range) | 59 (40-73) |
| Histology | |
| Follicular NHL grade 1* | 15 |
| Follicular NHL grade 2* | 2 |
| Diffuse large B cell NHL* | 2 |
| Small lymphocytic NHL* | 1 |
| Previous therapy | |
| CHOP | 9 |
| CVP | 9 |
| Rituximab | 7 |
| Oral alkylating agents | 4 |
| Purine analog chemotherapy | 3 |
| Other combination chemotherapy | 4 |
| Autologous stem cell transplantation | 2 |
| Ibritumomab tiuxetan | 1 |
Characteristics . | No. . |
|---|---|
| Total enrolled | 20 |
| Women/men | 11/9 |
| Mean age, y (range) | 59 (40-73) |
| Histology | |
| Follicular NHL grade 1* | 15 |
| Follicular NHL grade 2* | 2 |
| Diffuse large B cell NHL* | 2 |
| Small lymphocytic NHL* | 1 |
| Previous therapy | |
| CHOP | 9 |
| CVP | 9 |
| Rituximab | 7 |
| Oral alkylating agents | 4 |
| Purine analog chemotherapy | 3 |
| Other combination chemotherapy | 4 |
| Autologous stem cell transplantation | 2 |
| Ibritumomab tiuxetan | 1 |
CHOP indicates cyclophosphamide, hydroxydaunomycin/doxorubicin, Oncovin, prednisone; CVP, cyclophosphamide, vincristine, prednisone.
World Health Organization lymphoma classification.